Amy Armstrong

Profile picture

phone: (314) 454-6018


  • BA, Highest Honors and Summa Cum Laude, University of North Carolina at Chapel Hill2006
  • MD, Virginia Commonwealth University/Medical College of Virginia2012


  • Pediatric Residency, Northwestern University/Ann & Robert H. Lurie Children's Hospital of Chicago2012 - 2015
  • Pediatric Hematology/Oncology Fellowship, Northwestern/Ann & Robert H. Lurie Children's Hospital of Chicago2015 - 2018

Licensure and Board Certification

  • MO, License of Physician and Surgeon
  • IL, License of Physician and Surgeon
  • 2015Pediatrics
  • 2019Pediatric Hematology/Oncology

Honors and Awards

  • James M. Johnston Scholarship, UNC-Chapel Hill2002 - 2006
  • Phi Beta Kappa, UNC-Chapel Hill2005
  • Patrick F. Earey Chancellor’s Award, UNC-Chapel Hill2006
  • Pediatric Elizabeth Joanne Harbison Memorial Award, VCU School of Medicine2012
  • Young Investigator Award, Pediatric Bone Marrow Transplant Consortium2014
  • Alpha Omega Alpha, Northwestern University Feinberg School of Medicine2015
  • Exemplary Model of Professionalism, Northwestern University/McGaw Medical Center2018
  • Red Shoes Award for quality, family-centered care, Riley Hospital for Children2019

Recent Publications view all (22)

Publication Co-Authors

  1. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials. Expert Opin Investig Drugs. 2021;1-10. PMID:34932916 
  2. Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma. Genes (Basel). 2021;12(10). PMCID:PMC8535289  PMID:34680895 
  3. Cutaneous reactions to pediatric cancer treatment: Part I. Conventional chemotherapy. Pediatr Dermatol. 2021;38(1):8-17. PMID:33170534 
  4. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat Med. 2021;27(1):165-173. PMCID:PMC8275010  PMID:33442015 
  5. Neurofibromatosis type 1-related tumours in paediatrics: an evolving treatment landscape. Lancet Child Adolesc Health. 2020. PMID:32562630 
  6. Early Administration of Imatinib Mesylate Reduces Plexiform Neurofibroma Tumor Burden with Durable Results after Drug Discontinuation in a Mouse Model of Neurofibromatosis Type 1 Pediatric Blood Cancer. 2020. PMID:32459399 
  7. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Hum Mol Genet. 2019;28(16):2752-2762. PMCID:PMC6687955  PMID:31091306 
  8. Noninvasive Diagnosis of Infection Using Plasma Next-Generation Sequencing: A Single-Center Experience Open Forum Infect Dis. 2019. PMID:31375834 
  9. Cell-free DNA next-generation sequencing successfully detects infectious pathogens in pediatric oncology and hematopoietic stem cell transplant patients at risk for invasive fungal disease. Pediatr Blood Cancer. 2019;66(7):e27734. PMID:30941906 
  10. 5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype. JCO Precis Oncol. 2019;3. PMCID:PMC6553657  PMID:31179414 
  11. Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation. Pediatr Blood Cancer. 2019;66(1):e27493. PMID:30318721 
  12. A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study. PLoS One. 2018;13(12):e0208936. PMCID:PMC6292605  PMID:30543698 
  13. Proximal Hypospadias and a Novel WT1 Variant: When Should Genetic Testing Be Considered? Pediatrics. 2018;141(Suppl 5):S491-S495. PMID:29610178 
  14. Current Knowledge and Practice of Pediatric Providers in Umbilical Cord Blood Banking. Clin Pediatr (Phila). 2018;57(2):161-167. PMID:28952356 
  15. Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants. J Pediatr Hematol Oncol. 2018;40(1):31-35. PMID:28538090 
  16. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat Genet. 2017;49(10):1487-1494. PMCID:PMC5712232  PMID:28825729 
  17. The Impact of High-resolution HLA-A, HLA-B, HLA-C, and HLA-DRB1 on Transplant-related Outcomes in Single-unit Umbilical Cord Blood Transplantation in Pediatric Patients. J Pediatr Hematol Oncol. 2017;39(1):26-32. PMID:27820121 
  18. Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome. Pediatr Blood Cancer. 2015;62(11):2007-10. PMID:26011159 
  19. Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis. Pediatr Blood Cancer. 2014;61(5):949-50. PMID:24273036 
  20. Graft-versus-host disease after solid organ transplantation: a single center experience and review of literature. Ann Transplant. 2012;17(4):133-9. PMID:23274334 
  21. Giant cell tumor of rib arising anteriorly as a large inframammary mass: a case report and review of the literature. Case Rep Med. 2012;2012:850509. PMCID:PMC3522514  PMID:23251185 
  22. Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine. 2011;29(15):2705-11. PMCID:PMC3084484  PMID:21310190 
Last updated: 02/16/2022
© 2022 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130